Since TFEB silencing induced chemo-immuno-resistance in NSCLC cells, a potential strategy to re-sensitize cells with low TFEB to PT and Vγ9Vδ2 T-lymphocytes killing, could be increasing the amount of IPP without reducing the amount of cholesterol. The gene discussed is TFEB; the disease is non-small cell lung carcinoma.